- Dai-Ichi Life has increased its forecast for the fiscal year net income to 385 billion yen, up from the previous estimate of 323 billion yen. Analysts had estimated this figure to be 361.73 billion yen.
- The company anticipates net sales to reach 10.19 trillion yen. Previously announced sales were 8.92 trillion yen, with estimations sitting at 10.24 trillion yen.
- Dai-Ichi Life projects a dividend of 133 yen, compared to the earlier amount of 122 yen, with analyst expectations at 126.06 yen.
- For the third quarter, the firm reported a net income of 120.52 billion yen, substantially surpassing the analyst estimate of 92.31 billion yen.
- Current market recommendations for Dai-Ichi Life include 11 “buys,” 2 “holds,” and 1 “sell.”
A look at Dai Ichi Life Insurance Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 5 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 4.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
When looking at the long-term outlook for Dai Ichi Life Insurance, the Smartkarma Smart Scores paint a promising picture. With a high score in Dividend and Momentum, the company appears to be in a strong position to provide attractive returns to investors while also showing positive growth potential. Coupled with solid scores in Value and Resilience, Dai Ichi Life Insurance seems well-equipped to weather market fluctuations and sustain its performance over time.
Dai Ichi Life Insurance, known for underwriting and selling various insurance products including life, health, and annuity plans, has garnered positive ratings across key factors. The company’s commitment to offering a diverse range of insurance solutions, from education funds for children to financial security for seniors, highlights its customer-centric approach and adaptability to changing market demands.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
